A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation
Objectives: The purpose of this study was to determine the efficacy and safety of intravenous
RSD1235 in terminating recent onset atrial fibrillation (AF). Background: Anti-arrhythmic …
RSD1235 in terminating recent onset atrial fibrillation (AF). Background: Anti-arrhythmic …
[PDF][PDF] Epidemiology and management of new-onset atrial fibrillation
K Abusaada, SB Sharma, R Jaladi… - Am J Manag Care, 2004 - academia.edu
Atrial fibrillation (AF) is a common acute or chronic cardiac disorder that can result in
significant morbidity and mortality. Its incidence in the United States is increasing …
significant morbidity and mortality. Its incidence in the United States is increasing …
Oral class III antiarrhythmics: what is new?
MH Khan - Current opinion in Cardiology, 2004 - journals.lww.com
Oral class III antiarrhythmics: what is new? : Current Opinion in Cardiology Oral class III
antiarrhythmics: what is new? : Current Opinion in Cardiology Log in or Register Subscribe to …
antiarrhythmics: what is new? : Current Opinion in Cardiology Log in or Register Subscribe to …
Comparison of intravenous ibutilide vs. propafenone for rapid termination of recent onset atrial fibrillation.
N Zhang, JH Guo, HC Zhang, XB Li… - … journal of clinical …, 2005 - search.ebscohost.com
This study was to evaluate the efficacy and safety of ibutilide and propafenone given
intravenously in converting recent onset atrial fibrillation (AF). Eighty-two consecutive …
intravenously in converting recent onset atrial fibrillation (AF). Eighty-two consecutive …
Use of ibutilide for cardioversion of recent-onset atrial fibrillation and flutter in elderly
RM Gowda, IA Khan, G Punukollu… - American journal of …, 2004 - journals.lww.com
Ibutilide is a class III antiarrhythmic drug used for pharmacological cardioversion of recent-
onset atrial fibrillation and flutter. The objective of the study was to assess the efficacy of …
onset atrial fibrillation and flutter. The objective of the study was to assess the efficacy of …
Pharmacological treatment of atrial fibrillation: mechanisms of action and efficacy of class III drugs
F Lombardi, P Terranova - Current medicinal chemistry, 2006 - ingentaconnect.com
Atrial fibrillation represents a major clinical, social and economical matter, and its
importance is expected to increase even more in the near future. The progressive ageing of …
importance is expected to increase even more in the near future. The progressive ageing of …
Ibutilide–recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation
SA Doggrell, JC Hancox - Expert Opinion on Investigational Drugs, 2005 - Taylor & Francis
Ibutilide is a 'pure'class III antiarrhythmic drug, used intravenously against atrial flutter and
fibrillation. At a cellular level it exerts two main actions: induction of a persistent Na+ current …
fibrillation. At a cellular level it exerts two main actions: induction of a persistent Na+ current …
Pharmacokinetic and pharmacodynamic properties of a single intravenous dose of ibutilide fumarate: a phase I, randomized, open-label, increasing-dose study in …
Y Li, L Tian, Y Huang, L Hua - Clinical therapeutics, 2007 - Elsevier
Background: Atrial flutter is a common sustained atrial tachyarrhythmia whose frequency
increases with age. Ibutilide is a class III antiarrhythmic agent used for the cardioversion of …
increases with age. Ibutilide is a class III antiarrhythmic agent used for the cardioversion of …